November 17, 2025
1 min read
Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China
Akeso, Inc. announced that its AK152, a novel bispecific antibody targeting both amyloid-beta and blood-brain barrier expressed receptor, has been granted approval by the National Medical Products...
P
Patterns Editorial
Editorial Team · November 17, 2025
Akeso, Inc. announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aß) and blood-brain barrier (BBB) expressed receptor, has been granted approval by the National Medical Products Administration (NMPA) to initiate clinical... [1781 chars]
